BACKGROUND The role of TAPSE/PASP, a measurement of right ventricular to pulmonary artery coupling, in patients hospitalized for acute heart failure (AHF) is poorly described. OBJECTIVES To evaluate the prognostic impact of TAPSE/PASP in AHF. METHODS This retrospective single-center study included patients hospitalized for AHF between January 2004 and May 2017. TAPSE/PASP was evaluated as a continuous variable and as tertiles according to its value on admission. The main outcome was the composite of 1-year all-cause death or heart failure hospitalization. RESULTS A total of 340 patients were included [mean age 68.8 ± 11.8 years; 76.2% men, mean left ventricular ejection fraction (LVEF) 30.4 ± 13.3%]. Patients with lower TAPSE/PASP had more comorbidities and a more advanced clinical profile, and received higher doses of intravenous furosemide in the first 24 h. There was a significant, linear, inverse relationship between TAPSE/PASP values and the incidence of the main outcome (P = 0.003). In two multivariable analyses including clinical (model 1), biochemical and imaging parameters (model 2) TAPSE/PASP ratio was independently associated with the primary end point [model 1: hazard ratio 0.813, 95% confidence interval (CI) 0.708-0.932, P = 0.003; model 2: hazard ratio 0.879, 95% CI 0.775-0.996, P = 0.043]. Patients with TAPSE/PASP greater than 0.47 mm/mmHg had a significantly lower risk of the primary end point (model 1: hazard ratio 0.473, 95% CI 0.277-0.808, P = 0.006; model 2: hazard ratio 0.582, 95% CI 0.355-0.955, P = 0.032; both compared with TAPSE/PASP <0.34 mm/mmHg). Similar findings were observed for 1-year all-cause mortality. CONCLUSION TAPSE/PASP on admission demonstrated a prognostic value among patients with AHF.

中文翻译：

---

三尖瓣环平面收缩压偏移/肺动脉收缩压比对急性心力衰竭住院患者的预后作用。

背景 TAPSE/PASP（一种右心室与肺动脉耦合的测量方法）在因急性心力衰竭 (AHF) 住院的患者中的作用很少被描述。目的 评估 TAPSE/PASP 对 AHF 的预后影响。方法 这项回顾性单中心研究纳入了 2004 年 1 月至 2017 年 5 月期间因 AHF 住院的患者。 TAPSE/PASP 根据入院时的值作为连续变量和三分位数进行评估。主要结局是一年全因死亡或心力衰竭住院的综合结果。结果 总共纳入 340 名患者[平均年龄 68.8 ± 11.8 岁；76.2% 男性，平均左心室射血分数 (LVEF) 30.4 ± 13.3%]。TAPSE/PASP 较低的患者有更多的合并症和更先进的临床特征，并且在前 24 小时内接受了更高剂量的静脉注射呋塞米。TAPSE/PASP 值与主要结局的发生率之间存在显着的线性负相关关系 (P = 0.003)。在两项多变量分析中，包括临床（模型 1）、生化和影像参数（模型 2），TAPSE/PASP 比率与主要终点独立相关[模型 1：风险比 0.813，95% 置信区间 (CI) 0.708-0.932， P=0.003；模型2：风险比0.879，95% CI 0.775-0.996，P = 0.043]。TAPSE/PASP 大于 0.47 mm/mmHg 的患者主要终点风险显着较低（模型 1：风险比 0.473，95% CI 0.277-0.808，P = 0.006；模型 2：风险比 0.582，95% CI 0.355-0.955，P = 0.032；均与 TAPSE/PASP <0.34 mm/mmHg 相比。对于一年全因死亡率也观察到类似的结果。结论 入院时 TAPSE/PASP 证明了 AHF 患者的预后价值。